Monitor ASCO presentations (May 30–June 1) for specific response rate, PFS, and OS data from the pumitamig and gotistobart abstracts — the interim data described is encouraging but lacks quantitative endpoints. The Phase 3 part of ROSETTA Lung-02 (pumitamig vs pembrolizumab) is the key catalyst to watch.
Price Chart
Executive Summary
BioNTech filed a 6-K announcing its upcoming presentations at the 2026 ASCO Annual Meeting, including new clinical data for pumitamig (Phase 2 ROSETTA Lung-02 in 1L NSCLC) and gotistobart (Phase 2 PRESERVE-004 in platinum-resistant ovarian cancer), plus four trial-in-progress posters across its ADC and immunotherapy pipeline. The filing is a routine pipeline update with no new financial data, guidance, or regulatory milestones — the clinical data disclosed is interim and descriptive, not definitive.
Key Facts
- BioNTech will present at ASCO 2026 (May 29–June 2) with two oral presentations and four poster presentations
- Pumitamig (PD-L1/VEGF-A bispecific) Phase 2 data in 1L NSCLC shows 'encouraging anti-tumor activity' — third global dataset with consistent signal
- Gotistobart (CTLA-4) Phase 2 data in platinum-resistant ovarian cancer shows 'durable anti-tumor activity and clinically meaningful overall survival'
- Company has 25+ Phase 2/3 trials including 13 ongoing pivotal trials and novel-novel combination trials including ADCs
- No financial figures, guidance, or regulatory submission timelines were disclosed in the filing
Financial Impact
No financial data provided; pipeline update only
Risk Factors
- Interim Phase 2 data may not replicate in larger Phase 3 trials
- No regulatory filing or approval timeline provided — pipeline remains early-stage for these assets
- Competitive landscape in 1L NSCLC (pembrolizumab standard of care) and platinum-resistant ovarian cancer (limited approved options) creates high bar for differentiation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000037 |
| Document: form6-kascocurtainraiser22.htm | 0001776985-26-000037 |
| Document: 0001776985-26-000037-index-headers.html | 0001776985-26-000037 |
| Document: 0001776985-26-000037-index.html | 0001776985-26-000037 |
| Document: 0001776985-26-000037.txt | 0001776985-26-000037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.61 (+5.36%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.61 (−12.88%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.61 (+4.10%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.61 (−5.75%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.61 (+4.04%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.61 (+12.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access